Study of Efficacy and Safety of Inclisiran in Japanese Participants With High Cardiovascular Risk and Elevated LDL-C
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 312 participants.
Also called NCT04666298
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 312 participants
- Sponsor
- Registry
-
NCT04666298
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT04666298. Randomized; quadruple masking; primary purpose treatment. Start 2021-01-29 (actual); primary completion 2022-04-18 (actual). Results posted on 2023-05-10.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of Efficacy and Safety of Inclisiran in Japanese Participants With High Cardiovascular Risk and Elevated LDL-C
- Acronym
- ORION-15
- Condition
- Hypercholesterolemia
- Condition
- Heterozygous Familial Hypercholesterolemia
- Intervention (Drug)
- Inclisiran sodium
- Intervention (Drug)
- Placebo
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct04666298- Content hash
dcaa69c03b1d7c13376c62e17ac3bab51ea6033dd3fa666835dab9c1e1b9fa81